Bonus Biogroup: How Much Dilution Is Still Needed To Reach Phase III

The main article already established that Bonus Biogroup’s central bottleneck is no longer scientific but financial. This follow-up isolates one narrower question: how much capital is actually visible today, how much of it is already translating into dilution, and how much more is still likely to be needed if the company truly wants to reach Phase III rather than merely survive to the next reporting date.

There are four points that matter most here:

• The 2025 bridge did not come only from the market. Part of it came from related-party balances swelling to NIS 7.88 million.
• The equity raised after year end is bridge capital, not full Phase III capital. Even the NIS 9.173 million announced in early 2026 is still below the NIS 12.241 million working capital deficit reported at year end.
• The U.S. transaction is the only layer that approaches the needed scale, but even it is smaller than the disclosed budget for the two Phase III programs targeted for 2026.
• Dilution is no longer abstract. The visible path already reaches about 2.57% even before Nasdaq, and about 9.56% to 11.43% if the possible U.S. offering, local warrants, and the underwriter option are all added.

What Really Held The Bridge Until March 2026

The right place to start is not the trial budget, but cash. Bonus ended 2025 with only NIS 228 thousand of cash, a working capital deficit of NIS 12.241 million, an annual loss of NIS 24.5 million, and negative operating cash flow of NIS 14.933 million. In the same breath, the company states that existing funding sources are not sufficient for the next 12 months and are also not sufficient to complete development through commercial production and sales.

What matters more is that this gap was not bridged only by new investors. At year end, payables to interested parties stood at NIS 7.88 million, versus NIS 3.038 million a year earlier. Of that balance, NIS 4.434 million related to the chairman’s unpaid compensation and NIS 3.355 million to the CEO’s unpaid compensation. In parallel, the operating cash flow bridge shows that the increase in balances with interested parties contributed NIS 4.909 million to working capital and reduced the reported cash burn.

That point is critical because the meaning is straightforward: part of the 2025 funding bridge came from money that did not leave the company. This is not bank debt, and it is not fresh outside equity. It is effectively internal bridge financing from management and the chairman. Set that against the NIS 8.012 million the company actually received after the balance sheet date, and the picture becomes more uncomfortable: the unpaid related-party balance is almost the same size as all of the cash the company managed to bring in from the start of 2026 until the accounts were approved.

This chart matters because it makes clear that the market did provide air, but that air still does not close the basic hole in the balance sheet. Even if the full NIS 9.173 million from the January to March agreements is ultimately collected, that amount still sits NIS 3.068 million below the working capital deficit recorded at year end. So the local 2026 layer is first and foremost a survival bridge. It does not yet look like fully committed Phase III funding.

What It Really Costs To Reach Phase III

To understand the dilution question, the analysis has to move from the balance sheet to the budget table. The company discloses three future Phase III trials with patient counts, site counts, and explicit budgets. Two of them create financing pressure already in 2026.

The key point is that a Phase III discussion at Bonus is not a discussion about one $5 million trial. The company itself has put forward a $17 million budget for two Phase III programs that converge on the same year. That changes the dilution read completely.

This is where the central gap appears. The possible U.S. transaction is structured around a gross raise of $15 million before underwriting fees and expenses. That means even if it closes in full, it covers only about 88.2% of the disclosed budget for the two 2026 Phase III programs, before fees and before corporate overhead, payroll, rent, materials, and the ongoing cost base of the company. That is no longer an aggressive interpretation. It is the company’s own math.

The analytical implication is that the U.S. move, even in a favorable scenario, still does not look like comfortable funding for both tracks in parallel. That leads to the most reasonable inference from the documents: the company will need one of three things, to prioritize one program over the other, to bring in a commercial or strategic partner that absorbs part of the cost, or to come back to the equity market again.

The Visible 2026 Capital Stack

After the balance sheet date, Bonus built its 2026 capital stack in several layers, and they are not equal in quality.

The first layer is local. Five investment rounds approved between January 7 and March 11, 2026 amount to NIS 9.173 million. They come at share prices between NIS 0.40 and NIS 0.63, with a weighted average price of about NIS 0.55 per share. This is no longer the funding backdrop of late 2025, and that is an improvement. But it is still small money relative to what Phase III actually requires.

The second layer is the March 19 amendment. Here there is a genuine quality improvement: instead of 11,030,000 shares at NIS 0.30, the company approved 4,950,794 shares at NIS 0.63 for NIS 3.119 million. That matters, because it shows that better market terms can lift the price of capital and sharply reduce the share count needed in a financing round. But it also needs to be said plainly: better terms do not solve a scale problem.

The third layer is the U.S. move, and it is the only layer trying to close the gap on something close to a Phase III scale. Under the filing, the company is contemplating 3 million ADS, each representing 30 ordinary shares, at $4 to $6 per ADS, with a 15% green shoe option. But the same filing explicitly says that completion, terms, and Nasdaq listing are not certain, depend on market conditions, SEC and Nasdaq reviews, and that no final corporate decision had yet been made on the transaction.

This is where the March 2026 roadshow presentation also matters. Management is selling a very clean story to the room: two advanced assets, entry into Phase III in 2026, no debt, and an evaluation of a leading commercialization partner for the U.S. market. That is a sensible pitch. But for outside shareholders, it carries one clear meaning: if there is no debt and the partner is still only being evaluated, the bridge remains overwhelmingly equity-funded. The question is no longer whether dilution will happen, but how much of it arrives before a less dilutive capital source appears.

How Much Dilution Is Already Visible, And How Much Is Probably Still Ahead

This chart gives the direct answer to the title. Without Nasdaq, the dilution already sitting on the table amounts to about 1.43% from the January to March share issuances, another 0.71% if the local warrants are exercised, and another 0.42% from the amended NIS 0.63 placement. Put differently, even before the U.S. market enters the story, the current path already points to about 2.57% visible dilution.

If the possible U.S. offering closes in the structure that was published, it alone adds about 7.70% dilution. Add the local warrants, and the visible path rises to about 10.27%. Add the full underwriter option, and it moves to about 11.43%.

These numbers do not mean all of this dilution must happen. They mean that the visible path is already in the low double digits if all currently disclosed layers materialize, and even that may not be the end of the story. The reason is simple: $15 million gross is a large transaction for a company of Bonus’s size, but it is still not equal to the budget for the two 2026 Phase III programs plus the company’s overhead and ongoing operations.

That leads to the most defensible inference from the documents: the road to Phase III probably will not be a straight line of one raise and done. If the company secures a real commercial partner, part of the gap may close without another direct equity layer. If it does not, the more likely path is prioritization between programs, a staged start to the trials, or another return to the equity market after the U.S. process becomes clearer.

Conclusion

The title now has a sharper answer. Bonus has already shown in 2026 that it can improve financing terms, lift the price of capital from NIS 0.30 to NIS 0.63 in one case, and build a local bridge of more than NIS 9 million. But that is still a bridge that carries the company forward. It is not yet a layer that comfortably closes the Phase III math.

The easiest thing to miss is that the current bridge rests on three legs at once: relatively small local equity, compensation that has not yet been drawn by related parties, and a U.S. transaction that is still not certain. Until those three legs are replaced by a larger and harder source of funding, dilution remains the core of the story.

So the practical answer is this: the dilution already visible in the documents runs from about 2.57% without Nasdaq to about 9.56% to 11.43% if all of the currently disclosed layers are completed. And even then, if the company tries to fund both 2026 Phase III paths without prioritization and without a partner, it is hard to see the dilution story ending there.